P-93 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION IN A PUBLIC HOSPITAL IN CHILE BETWEEN YEARS 2015 AND 2022

No The prevalence of hepatitis B virus (HBV) in Chile is 0.54%. Antiviral treatment is guaranteed by a ministerial program for infected people who meet treatment criteria. To date, the serological response rate in Chile has not been reported. Objectives: To determine the frequency of normalization of alanine aminotrasferasa (ALT), HBV Deoxyribonucleic Acid (DNA), loss of e (HBeAg) and superficial (HBsAg) antigens in adult patients with chronic HBV infection treated with antivirals in a public hospital in Chile. Observational, retrospective study including adults with chronic HBV infection, without immunodeficiency, controlled in hepatology policlinic between 2015 and 2022 at Hospital del Salvador. Descriptive statistics were used to determine the demographic characteristics of this population, criteria for indication of antiviral therapy and surrogate markers of therapeutic targets. 180 clinical records were reviewed. 141 were excluded: poor treatment adherence and follow-up (30), deceased (59), acute HBV infection (33) and immunodeficiency (19). 39 patients were included in the analysis, being 61.5% men and 25.6% with evidence of cirrhosis at diagnosis. 21 patients (53.8%) received antiviral therapy, 14 of them (66.6%) receiving entecavir. The most frequent treatment criteria was viral load > 2000 plus ALT > 1.1 times above normal, followed by evidence of cirrhosis. 88.8% of treated patients achieved normal ALT at follow-up. 51.2% achieved undetectable HBV DNA. 23% (9) were HBeAg positive with 4 of them achieving negative HBeAg. None achieved loss of HBsAg. Most patients achieved normal ALT and HVB DNA levels with treatment. There is a significant number of patients who did not adhere to medical controls and there is no protocol for serological follow-up, making it difficult to select candidates for antiviral suspension.